Company: DAWN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0000950170-25-026654
Chunk: 7

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 15
Chunk 7
---
4, 2021, by and between Day One Biopharmaceuticals Holding Co., LLC and Millennium Pharmaceuticals, Inc.
     
    S-1
     
    333-255754
     
    May 4, 2021

    10.11†
     
    Amendment No. 1 to the License Agreement for RAF, dated March 4, 2024, by and between Day One Biopharmaceuticals, Inc. and Sunesis Pharmaceuticals, Inc.
     
    8-K
     
    001-40431
     
    March 7, 2024

    10.12†*
     
    Asset Purchase Agreement, dated May 29, 2024.
     
    10-Q
     
    001-40431
     
    August 2, 2024

    10.13†*
     
    Exclusive License Agreement by and between MabCare Therapeutics and Day One Biopharmaceuticals, Inc. dated June 17, 2024. 
     
    10-Q
     
    001-40431
     
    August 2, 2024

    10.14†*
     
    Exclusive License Agreement by and between Day One Biopharmaceuticals, Inc. and Ipsen Pharma SAS dated July 23, 2024.
     
    10-Q 
     
    001-40431
     
    October 30, 2024

    19.1
     
    Insider Trading Policy

    X

    21.1
     
    Subsidiaries of the Registrant

    X

129

    23.1
     
    Consent of Pricewaterhouse Coopers LLP, Independent Registered Public Accounting Firm

    X

    23.2
     
    Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm

    X

    31.1
     
    Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

    X

    31.2
     
    Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of